Diclofenac sodium + Lidocaine hydrochloride monohydrate
Olfen 75 belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs), which are used to treat pain and inflammation.
Olfen 75 is intended for intramuscular injection and is administered only by qualified medical personnel.
Olfen 75 relieves symptoms of inflammatory conditions, such as swelling and pain. It does not affect the causes of inflammation and fever.
Olfen 75 can be used to treat severe pain and inflammation in cases of:
You should follow all instructions given by your doctor or pharmacist carefully, even if they differ from the general information contained in this leaflet.
When not to use Olfen 75:
1
Due to the presence of lidocaine, the solution for injection is contraindicated in cases of:
If any of the above symptoms occur in you, you should inform your doctor and not take Olfen 75 until your doctor decides that the medicine is suitable for you.
You should discuss the use of Olfen 75 with your doctor, pharmacist, or nurse before starting treatment.
You should inform your doctor if:
2
Before taking diclofenac, you should inform your doctor:
Before using Olfen 75, you should tell your doctor if you have recently undergone or are scheduled to undergo stomach or gastrointestinal surgery, as Olfen 75 may sometimes cause impaired wound healing in the intestines after surgery.
You should strictly follow the recommendations for administering the intramuscular injection to avoid side effects at the injection site, which can lead to muscle weakness, muscle paralysis, decreased sensation, and necrosis at the injection site.
The occurrence of side effects can be limited by using the medicine in the smallest effective dose and for no longer than necessary.
If any of the above warnings apply to you, you should inform your doctor before using Olfen 75.
Other special warnings
Due to the presence of lidocaine, Olfen 75 should be used with particular caution in patients with myasthenia.
Olfen 75 should not be used at the same time as other systemically acting non-steroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors.
The use of medicines such as Olfen 75 may be associated with a small increased risk of heart attack ("myocardial infarction") or stroke. Any risk is more likely after taking high doses and long-term treatment. You should not exceed the recommended dose or treatment duration.
In case of heart problems, stroke, or suspected risk of these disorders (e.g., high blood pressure, diabetes, elevated cholesterol, or smoking), you should discuss the treatment with your doctor or pharmacist.
Olfen 75 may mask the symptoms of infection (e.g., headache, high temperature), making it more difficult to diagnose and treat the infection. If you feel unwell and need to see a doctor, you should inform them that you are taking Olfen 75.
In very rare cases, Olfen 75, like other anti-inflammatory medicines, may cause severe allergic skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome with widespread rash, high fever, and pain in the joints, as well as toxic epidermal necrolysis with skin and mucous membrane changes, high fever, and severe general condition). Therefore, you should inform your doctor if you experience such reactions. In rare cases, Olfen 75, like other anti-inflammatory medicines, may cause allergic reactions, including anaphylactic and pseudo-anaphylactic reactions, even if the product has not been used before.
Special precautions should be taken in patients with asthma, taking diclofenac parenterally due to the possibility of exacerbating asthma symptoms.
Olfen 75 should be administered only after careful consideration of the benefit-risk ratio in cases of:
3
Elderly
No dose adjustment is required.
Due to the profile of possible side effects, elderly patients should be closely monitored.
Elderly patients may be more sensitive to the effects of Olfen 75. Therefore, they should follow their doctor's recommendations very carefully and take the minimum dose of the medicine that ensures the relief of symptoms. It is particularly important for patients to report side effects to their doctor immediately.
Olfen 75 should not be used in children and adolescents under 18 years of age.
You should tell your doctor or pharmacist about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take.
It is particularly important to inform your doctor about taking any of the following medicines:
Lidocaine used at the same time as anti-arrhythmic medicines, beta-adrenergic blockers, or calcium antagonists may exhibit additional inhibitory effects on atrioventricular conduction, conduction of the cardiac impulse, and contractile force.
Taking non-steroidal anti-inflammatory medicines (NSAIDs), including Olfen 75, and alcohol at the same time may increase the risk of side effects associated with the administration of the medicine (in particular, those related to the gastrointestinal system or the central nervous system).
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, you should consult your doctor or pharmacist before using this medicine.
4
You should not take Olfen 75 if you are in the last three months of pregnancy, as it may harm the unborn child or cause complications during delivery. Olfen 75 may cause kidney and heart problems in the unborn child. It may also increase the risk of bleeding in you and your child and prolong labor. During the first six months of pregnancy, you should not use Olfen 75 unless your doctor considers it absolutely necessary. If treatment is necessary during this period or when trying to conceive, you should use the smallest dose for the shortest possible time. From the 20th week of pregnancy, Olfen 75 may cause kidney problems in the unborn child if taken for more than a few days. This may lead to a low level of amniotic fluid surrounding the child (oligohydramnios) or narrowing of the arterial duct (ductus arteriosus) in the child's heart. If treatment is required for a longer period, your doctor may recommend additional monitoring.
You should not breastfeed if you are taking Olfen 75, as the medicine may have a harmful effect on the baby.
Diclofenac may make it more difficult to become pregnant. You should inform your doctor if you plan to become pregnant or are having trouble becoming pregnant.
You should not drive vehicles or operate any machines if you experience side effects while taking Olfen 75, such as vision disturbances, dizziness, dizziness of the labyrinth type, or drowsiness or other central nervous system disorders.
The medicine contains less than 1 mmol (23 mg) of sodium per 2 ml of solution (in one ampoule), which means the medicine is considered "sodium-free".
The medicine contains 480 mg of propylene glycol in each 2 ml ampoule.
This medicine should always be used as directed by your doctor, pharmacist, or nurse. If you are unsure, you should consult your doctor, pharmacist, or nurse.
Olfen 75 is administered only by qualified medical personnel.
Your doctor will decide when and how to use Olfen 75. The medicine should be administered intramuscularly. The injection is usually given in the buttock.
It is essential that your doctor uses the lowest effective dose to control pain for the shortest possible period.
Exceptionally, in severe cases (e.g., colic pain), the daily dose may be increased to two injections of 75 mg, at an interval of several hours (one injection in each buttock). One 75 mg ampoule can also be administered in combination with another form of Olfen (tablets, suppositories), without exceeding a total daily dose of 150 mg.
Adults
Olfen 75 is particularly indicated when rapid control of symptoms is required or when treatment with oral or rectal products is not possible. Olfen 75 should be administered as a single intramuscular injection (75 mg of diclofenac sodium).
5
Olfen 75 should not be used for more than 2 days. If further treatment is necessary, other forms of the medicine should be used, i.e., oral or rectal. You should not exceed the maximum daily dose of 150 mg of diclofenac sodium.
Children and adolescents
Olfen 75 should not be used in children and adolescents under 18 years of age.
If you suspect that you have used a higher dose of Olfen 75 than recommended, you should contact your doctor or nurse.
You should not take a double dose to make up for a missed dose.
If you have any further doubts about using this medicine, you should consult your doctor, pharmacist, or nurse.
If you have any further doubts about using this medicine, you should consult your doctor or pharmacist.
Like all medicines, Olfen 75 can cause side effects, although not everybody gets them.
Some side effects may be serious.
During treatment with Olfen 75, the following side effects have occurred with the following frequency:
Very common: more than 1 in 10 patients; common: 1 to 10 in 100 patients; uncommon: 1 to 10 in 1000 patients; rare: 1 to 10 in 10,000 patients; very rare: less than 1 in 10,000 patients; frequency not known (frequency cannot be estimated from available data).
6
If you experience any of the above symptoms, you should inform your doctor immediately.
Very common:occur in more than 1 in 10 patients
Common:occur in 1 to 10 in 100 patients
Uncommon:occur in 1 to 10 in 1000 patients
7
Rare:occur in 1 to 10 in 10,000 patients
Very rare:occur in less than 1 in 10,000 patients
Frequency not known:
Intramuscular administration can often cause local side effects at the injection site (burning sensation) or tissue damage, such as sterile abscess or fat and skin necrosis (Nicolau's syndrome).
Medicines like diclofenac may slightly increase the risk of myocardial infarction or stroke. The risk of this is more likely after taking high doses and long-term treatment. You should not exceed the recommended dose or treatment duration.
Additional effect of lidocaine:
Rarely, hypersensitivity reactions have been reported in the form of urticaria, edema, bronchospasm, or respiratory failure syndrome.
Due to the presence of lidocaine, rapid administration of the medicine (unintentional intravenous injection, injection into well-vascularized tissue) or overdose may cause systemic reactions, such as dizziness, drowsiness, seizures, confusion, nausea, vomiting, bradycardia, arrhythmias, decreased blood pressure to the level observed in shock.
You should inform your doctor if you experience any of the above side effects.
If you experience any side effects, including those not listed in this leaflet, you should consult your doctor, pharmacist, or nurse.
If Olfen 75 is used for more than a few weeks, you should ensure regular, monitoring visits to your doctor to ensure that no unnoticed side effects have occurred.
If you experience any side effects, including those not listed in this leaflet, you should tell your doctor, pharmacist, or nurse.
Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warszawa
Phone: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton after EXP.
The expiry date refers to the last day of the month stated.
The batch number on the packaging is stated after "Batch number (Lot)" or "Lot".
Store in a temperature below 25°C. Ampoules should be stored in the carton to protect from light.
Medicines should not be disposed of via wastewater or household waste. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substances of the medicine are diclofenac sodium and lidocaine hydrochloride monohydrate.
Each ampoule contains 75 mg of diclofenac sodium and 20 mg of lidocaine hydrochloride monohydrate.
Clear to slightly yellowish solution in a 2 ml glass ampoule made of orange glass in a carton.
The packaging contains 5 ampoules of 2 ml each.
Not all pack sizes may be marketed.
Teva B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
Merckle GmbH,
Ludwig-Merckle-Strasse 3
89143 Blaubeuren, Germany
To obtain more detailed information, you should contact the representative of the marketing authorization holder:
Teva Pharmaceuticals Polska Sp. z o.o., phone: +48 22 345 93 00
Date of last revision of the leaflet:
10
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.